LINCOMYCIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lincomycin Hydrochloride, and what generic alternatives are available?
Lincomycin Hydrochloride is a drug marketed by Geneyork Pharms, Gland Pharma Ltd, Micro Labs, Slate Run Pharma, Watson Labs, and Xgen Pharms. and is included in six NDAs.
The generic ingredient in LINCOMYCIN HYDROCHLORIDE is lincomycin hydrochloride. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the lincomycin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lincomycin Hydrochloride
A generic version of LINCOMYCIN HYDROCHLORIDE was approved as lincomycin hydrochloride by XGEN PHARMS on June 4th, 2015.
Summary for LINCOMYCIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 6 |
NDAs: | 6 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 133 |
Clinical Trials: | 3 |
Patent Applications: | 1,114 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LINCOMYCIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for LINCOMYCIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Menzies School of Health Research | Phase 4 |
The Peter Doherty Institute for Infection and Immunity | Phase 4 |
Sunnybrook Health Sciences Centre | Phase 4 |